# Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

> **NCT05996627** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 82 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Belumosudil
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT05996627
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996627, "Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05996627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*